Publications by authors named "Maria V Andres"

Claim this Profile
C
CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.
Laura Carrillo-Serradell, Juan Antonio Piñeyroa, Pablo Bousquets-Muñoz, Violeta Planells-Romeo, Lucía Aragón-Serrano

Haematologica· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Single and Repeated Dosing of Anti-Inflammatory Human Umbilical Cord Mesenchymal Stromal Cells in a Mouse Model of Polymicrobial Sepsis.
Barbara Fazekas, Senthilkumar Alagesan, Luke Watson, Olivia Ng, Callum M Conroy, Maria Velascode Andres

Stem Cell Rev Rep· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial.
Berta Grau-Pujol, Daniel Camprubí-Ferrer, Helena Marti-Soler, Marc Fernández-Pardos, Clara Carreras-Abad

Trials· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory effects of soluble CD5 on experimental tumor models.
Inês T Simões, Fernando Aranda, Esther Carreras, Maria Velasco-de Andrés, Sergi Casadó-Llombart

Oncotarget· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of tideglusib in Alzheimer's disease.
Simon Lovestone, Mercè Boada, Bruno Dubois, Michael Hüll, Juha O Rinne

J Alzheimers Dis· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.
Günter U Höglinger, Hans-Jürgen Huppertz, Stefan Wagenpfeil, María V Andrés, Vincente Belloch

Mov Disord· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.
Eduardo Tolosa, Irene Litvan, Günter U Höglinger, David Burn, Andrew Lees

Mov Disord· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.
Teodoro del Ser, Klaus C Steinwachs, Hermann J Gertz, María V Andrés, Belén Gómez-Carrillo

J Alzheimers Dis· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis